Get started
Author

Yun Gyoo Lee

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
2024 · Myung-Ju Ahn, Kentaro Tanaka, et al. · Journal of Clinical Oncology · 237
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
2019 · James Chih-Hsin Yang, Frances A. Shepherd, et al. · Journal of Thoracic Oncology · 210
PDF
Efficacy and Safety of Hepatic Arterial Infusion of Fluorouracil with Leucovorin as Salvage Treatment for Refractory Liver Metastases from Colorectal Cancer
2011 · Hyun Jung Lee, Yoon Soo Lee, et al. · The Korean Journal of Internal Medicine · 5
PDF
Survey of Medical Oncology Status in Korea (SOMOS-K): A National Survey of Medical Oncologists in the Korean Association for Clinical Oncology (KACO)
2016 · Do Yeun Kim, Yun Gyoo Lee, et al. · Cancer Research and Treatment · 4
Works count: 6
Citation count: 3,420
H-index: 5
I10-index: 4
Year
Topic
Type